[Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease]

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Cardiovascular disease (CVD) is a leading cause of death in chronic kidney disease (CKD) patients.
• CKD, indicated by albuminuria or reduced glomerular filtration rate, independently elevates cardiovascular risk.
• CKD involves both traditional and unique cardiovascular risk factors.

Purpose of the Study:

• To review the roles of arterial hypertension and dyslipidemia in CKD-associated cardiovascular outcomes.
• To emphasize the importance of managing these risk factors in CKD patients.

Main Methods:

• Review of interventional trials and clinical guidelines.
• Analysis of the impact of blood pressure and lipid profile normalization on cardiovascular events and mortality.

Main Results:

• Blood pressure reduction and lipid profile normalization significantly decrease major cardiovascular events and mortality.
• National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines identify CKD patients as high-risk for cardiovascular events.

Conclusions:

• Strict blood pressure control and renin-angiotensin system blockade are recommended for CKD patients.
• Use of statins to achieve target LDL cholesterol levels < 100 mg/dl is advised for CKD patients.
• Aggressive management of hypertension and dyslipidemia is essential for improving cardiovascular outcomes in CKD.